Non-statin lipid-lowering therapy over time in very-high-risk patients: effectiveness of fixed-dose statin/ezetimibe com
- PDF / 2,240,823 Bytes
- 10 Pages / 595.276 x 790.866 pts Page_size
- 26 Downloads / 172 Views
ORIGINAL PAPER
Non‑statin lipid‑lowering therapy over time in very‑high‑risk patients: effectiveness of fixed‑dose statin/ezetimibe compared to separate pill combination on LDL‑C Julius L. Katzmann1 · Francesc Sorio‑Vilela2 · Eugen Dornstauder3 · Uwe Fraas3 · Timo Smieszek4 · Sofia Zappacosta4 · Ulrich Laufs1 Received: 26 May 2020 / Accepted: 3 September 2020 © The Author(s) 2020
Abstract Background Many patients at very-high atherosclerotic cardiovascular disease risk do not reach guideline-recommended targets for LDL-C. There is a lack of data on real-world use of non-statin lipid-lowering therapies (LLT) and little is known on the effectiveness of fixed-dose combinations (FDC). We therefore studied prescription trends in oral non-statin LLT and their effects on LDL-C. Methods A retrospective analysis was conducted of electronic medical records of outpatients at very-high cardiovascular risk treated by general practitioners (GPs) and cardiologists, and prescribed LLT in Germany between 2013 and 2018. Results Data from 311,242 patients were analysed. Prescriptions for high-potency statins (atorvastatin and rosuvastatin) increased from 10.4% and 25.8% of patients treated by GPs and cardiologists, respectively, in 2013, to 34.7% and 58.3% in 2018. Prescription for non-statin LLT remained stable throughout the period and low especially for GPs. Ezetimibe was the most prescribed non-statin LLT in 2018 (GPs, 76.1%; cardiologists, 92.8%). Addition of ezetimibe in patients already prescribed a statin reduced LDL-C by an additional 23.8% (32.3 ± 38.4 mg/dL), with a greater reduction with FDC [reduction 28.4% (40.0 ± 39.1 mg/dL)] as compared to separate pills [19.4% (27.5 ± 33.8 mg/dL)]; p
Data Loading...
